Galegenimab, a newly developed agent, is creating considerable buzz within the medical community. This groundbreaking substance functions as an inhibitor of TIGIT, a checkpoint protein, which demonstrates a https://bookmarklinking.com/story11507591/galegenimab-a-promising-possibility-in-cancer-treatment